Safety and efficacy outcomes of protamine administration for heparin reversal following cryoballoon-based pulmonary vein isolation

Journal of Interventional Cardiac Electrophysiology

Volumn 43, Issue 2, 2015, Pages 161-167

  Gurses, Kadri Murat ^a   Kocyigit, Duygu ^a   Yalcin, Muhammed Ulvi ^a   Evranos, Banu ^a   Yorgun, Hikmet ^a   Sahiner, Mehmet Levent ^a   Kaya, Ergun Baris ^a   Oto, Mehmet Ali ^a   Ozer, Necla ^a   Aytemir, Kudret ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Atrial fibrillation; Cryoablation; Efficacy; Protamine; Safety

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; HEPARIN; PROTAMINE SULFATE; ANTICOAGULANT AGENT; HEPARIN ANTAGONIST; PROTAMINE;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD CLOTTING; CATHETER ABLATION; CONTROLLED STUDY; CRYOBALLOON BASED PULMONARY VEIN ISOLATION; DEEP VEIN THROMBOSIS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; FALSE ANEURYSM; FEMALE; FEMORAL ARTERIOVENOUS FISTULA; HEMATOMA; HEMOSTASIS; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAROXYSMAL ATRIAL FIBRILLATION; PERSISTENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; PULMONARY VEIN ISOLATION; RASH; VASCULAR ACCESS; ATRIAL FIBRILLATION; CRYOSURGERY; MIDDLE AGED; PROCEDURES; PULMONARY VEIN; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CRYOSURGERY; FEMALE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROTAMINES; PULMONARY VEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84933674936     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-015-9989-0     Document Type: Article

References (23)

1. January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Jr., et al. (2014). 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, 130(23), 2071–2104.
2. Hagens, V. E., Ranchor, A. V., Van Sonderen, E., Bosker, H. A., Kamp, O., Tijssen, J. G., et al. (2004). Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. Journal of the American College of Cardiology, 43(2), 241–247.
3. Viles-Gonzalez, J. F., & Mehta, D. (2011). Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation. Current Cardiology Reports, 13(1), 38–42.
4. Calkins, H., Kuck, K. H., Cappato, R., Brugada, J., Camm, A. J., Chen, S. A., et al. (2012). 2012 HRS/EHRA/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace, 14(4), 528–606.
5. Patel, A. A., Clyne, C. A., Henyan, N. N., White, C. M., Zembrowski, B. F., Migeed, M., et al. (2007). The use of protamine after radiofrequency catheter ablation: a pilot study. Journal of Interventional Cardiac Electrophysiology, 18(2), 155–158.
6. Conte, G., de Asmundis, C., Baltogiannis, G., Di Giovanni, G., Ciconte, G., Sieira, J., et al. (2014). Periprocedural outcomes of prophylactic protamine administration for reversal of heparin after cryoballoon ablation of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 41(2), 129–134.
7. Camm, A. J., Lip, G. Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., et al. (2012). 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Europace, 14(10), 1385–1413.
8. Aytemir, K., Gurses, K. M., Yalcin, M. U., Kocyigit, D., Dural, M., Evranos, B., et al. (2014). Safety and efficacy outcomes in patients undergoing pulmonary vein isolation with second-generation cryoballoon†. Europace. 2014 Nov 5. pii: euu273. [Epub ahead of print].
9. Garcia, D. A., Baglin, T. P., Weitz, J. I., Samama, M. M., & American College of Chest, P. (2012). Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(2 Suppl), e24S–e43S.
10. Cappato, R., Calkins, H., Chen, S. A., Davies, W., Iesaka, Y., Kalman, J., et al. (2010). Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. Arrhythmia and Electrophysiology, 3(1), 32–38.
11. Gaita, F., Caponi, D., Pianelli, M., Scaglione, M., Toso, E., Cesarani, F., et al. (2010). Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation, 122(17), 1667–1673.
12. Neumann, T., Kuniss, M., Conradi, G., Janin, S., Berkowitsch, A., Wojcik, M., et al. (2011). MEDAFI-Trial (Micro-embolization during ablation of atrial fibrillation): comparison of pulmonary vein isolation using cryoballoon technique vs. radiofrequency energy. Europace, 13(1), 37–44.
13. Herrera Siklody, C., Deneke, T., Hocini, M., Lehrmann, H., Shin, D. I., Miyazaki, S., et al. (2011). Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. Journal of the American College of Cardiology, 58(7), 681–688.
14. January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Jr., et al. (2014). 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 64(21), 2246–2280.
15. Abhishek, F., Heist, E. K., Barrett, C., Danik, S., Blendea, D., Correnti, C., et al. (2011). Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 30(3), 211–215.
16. Hoyt, H., Bhonsale, A., Chilukuri, K., Alhumaid, F., Needleman, M., Edwards, D., et al. (2011). Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. Heart Rhythm, 8(12), 1869–1874.
17. Cappato, R., Calkins, H., Chen, S. A., Davies, W., Iesaka, Y., Kalman, J., et al. (2005). Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation, 111(9), 1100–1105.
18. Di Biase, L., Burkhardt, J. D., Mohanty, P., Sanchez, J., Horton, R., Gallinghouse, G. J., et al. (2010). Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation, 121(23), 2550–2556.
19. Lakkireddy, D., Reddy, Y. M., Di Biase, L., Vanga, S. R., Santangeli, P., Swarup, V., et al. (2012). Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. Journal of the American College of Cardiology, 59(13), 1168–1174.
20. Chilukuri, K., Henrikson, C. A., Dalal, D., Scherr, D., MacPherson, E. C., Cheng, A., et al. (2009). Incidence and outcomes of protamine reactions in patients undergoing catheter ablation of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 25(3), 175–181.
21. Kuiper, K. K., & Nordrehaug, J. E. (2000). Early mobilization after protamine reversal of heparin following implantation of phosphorylcholine-coated stents in totally occluded coronary arteries. American Journal of Cardiology, 85(6), 698–702.
22. Pan, M., Suarez de Lezo, J., Medina, A., Romero, M., Hernandez, E., Segura, J., et al. (1997). In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation. American Journal of Cardiology, 80(10), 1336–1338.
23. Briguori, C., Di Mario, C., De Gregorio, J., Sheiban, I., Vaghetti, M., & Colombo, A. (1999). Administration of protamine after coronary stent deployment. American Heart Journal, 138(1 Pt 1), 64–68.